Growth hormone and prolactin responses to thyrotropin-releasing hormone in patients with severe liver disease.
Thyrotropin-releasing hormone (TRH) was administered iv to 10 patients with severe liver disease and 10 control subjects. Injection of 400 microgram TRH as a bolus induced in 7 out of 10 patients a clear-cut GH rise (larger than or equal 10 ng/ml) occurring 15-120 min after the injection, and no effect on GH levels in controls. Mean baseline GH levels wre higher in patients than in controls. An exaggerated and sustained PRL rise was present after TRH in the subjects with liver disease, whose mean baseline plasma PRL levels were within normal range.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002802:Cholinesterases / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006505:Hepatitis / Q000097:blood*; D006801:Humans; D007700:Kinetics; D008103:Liver Cirrhosis / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D012709:Serum Albumin / Q000032:analysis; D013973:Thyrotropin-Releasing Hormone; D014364:Tryptophan / Q000097:blood; D014508:Urea / Q000097:blood
D001786:Blood Glucose; D012709:Serum Albumin; D013973:Thyrotropin-Releasing Hormone; D014364:Tryptophan; D014508:Urea; D011388:Prolactin; D013006:Growth Hormone; D001219:Aspartate Aminotransferases; D002802:Cholinesterases; D000469:Alkaline Phosphatase; D001663:Bilirubin